TABLE 1.

Summary of active clinical trials involving latency-reversing agents^a

LRA	Secondary agent(s)	No. of patients	Status	Identifier
Nicotinamide (SIRT1 inhibitor)	Dendritic cell vaccine + auranofin + ART intensification	30	Active	NCT02961829
Vorinostat (HDACi)	ChAdV63.HIVconsv (ChAd) prime and MVA.HIVconsv boost vaccines	60	Active	NCT02336074
	Disulfiram	15	Terminated due to AE	NCT03198559
	HXTCb	12	Recruiting	NCT03212989
	Tamoxifen	30	Active	NCT03382834
	AGS-004 DC therapy	6	Terminated (AGS-004 supply unavailable)	NCT02707900 (VOR-VAX)
	VRC07-523LS	12	Recruiting	NCT03803605
Panobinostat (HDACi)	Pegylated IFN-α2a	34	Recruiting	NCT02471430
Romidepsin (HDACi)	3BNC117	30	Active	NCT02850016c
	MVA vector HIV vaccine + HIVACAR01 (personalized HIV vaccine) + 10-1074	56	Not yet recruiting	NCT03619278
	3BNC117 ab	60	Recruiting	NCT03041012
	3BNC117 ab	42	Not yet recruiting	RV 438
Valproic acid (HDACi)	Pyrimethamine	28	Recruiting	NCT03525730
Chidamide (HDACi)	None	60	Active	NCT02902185
	CAR-T or TCR-T-cell therapy	40	Recruiting	NCT03980691
Euphorbia kansui (ingenol) (PKC agonist)	None	9	Recruiting	NCT02531295
Lefitolimod (MGN1703) (TLR9 agonist)	10-1047 + 3BNC117	48	Recruiting	NCT03837756c
GS-9620 (TLR7 agonist)	None	28	Active	NCT03060447c
Pegylated IFN-α2a	None	54	Active	NCT02227277
	3BNC117 + 10-1074	21	Not yet recruiting	NCT03588715c
Recombinant human superagonist IL-15 (ALT-803/N-803)	None	10	Active	NCT02191098
	Haploidentical NK cell adoptive transfer	8	Recruiting	NCT03899480

^aBased on data from references 54 and 56. All treatments are in addition to ART, unless otherwise noted.

^bHXTC, HIV antigen expanded specific T-cell therapy.

^cThese studies involve analytical treatment interruption (ATI).